Lost Money on Amphastar Pharmaceuticals, Inc. (AMPH)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for potential violations of federal securities laws. This follows the FDA's issuance of a secondary complete response letter for Amphastar's generic teriparatide ANDA, AMP-015, after delays.
February 18, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after receiving a secondary CRL from the FDA for its generic teriparatide ANDA, AMP-015.
The investigation by Levi & Korsinsky and the FDA's secondary CRL for AMP-015 are likely to negatively impact Amphastar's stock price in the short term. The legal scrutiny and regulatory setbacks could lead to investor concerns and potential sell-offs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100